For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of this treatment and Tafamidis meglumine represents a true breakthrough . These groundbreaking therapies preserve the transthyretin protein, slowing its destructive build-up and